Littérature scientifique sur le sujet « FOOD AND DRUGS ADMINISTRATION »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « FOOD AND DRUGS ADMINISTRATION ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "FOOD AND DRUGS ADMINISTRATION"
Hutcheon, Duncan E. « Drugs Approved by Food & ; Drug Administration ». Journal of Clinical Pharmacology 29, no 5 (mai 1989) : 478–79. http://dx.doi.org/10.1002/j.1552-4604.1989.tb03366.x.
Texte intégralFurlan, Anthony J., et Marc Fisher. « Devices, Drugs, and the Food and Drug Administration ». Stroke 36, no 2 (février 2005) : 398–99. http://dx.doi.org/10.1161/01.str.0000153057.07181.94.
Texte intégralTsimberidou, Apostolia-Maria, Fadi Braiteh, David J. Stewart et Razelle Kurzrock. « Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial ». Journal of Clinical Oncology 27, no 36 (20 décembre 2009) : 6243–50. http://dx.doi.org/10.1200/jco.2009.23.6018.
Texte intégralHaffner, Marlene E., et John V. Kelsey. « Evaluation of Orphan Products by the U.S. Food and Drug Administration ». International Journal of Technology Assessment in Health Care 8, no 4 (1992) : 647–57. http://dx.doi.org/10.1017/s0266462300002348.
Texte intégralRangaraj, Nagarjun, Sunitha Sampathi, Vijayabhaskarreddy Junnuthula, Praveen Kolimi, Preethi Mandati, Sagar Narala, Dinesh Nyavanandi et Sathish Dyawanapelly. « Fast-Fed Variability : Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects ». Pharmaceutics 14, no 9 (27 août 2022) : 1807. http://dx.doi.org/10.3390/pharmaceutics14091807.
Texte intégralKharitonovа, L. A., A. M. Zaprudnov et K. I. Grigoriev. « Mandatory assessment of trophological status and nutrition in children in drugs prescribing ». Experimental and Clinical Gastroenterology, no 1 (2 mai 2020) : 4–14. http://dx.doi.org/10.31146/1682-8658-ecg-173-1-4-14.
Texte intégralSharma, Ajitha, et Rathnakar Up. « REVISED FOOD AND DRUG ADMINISTRATION RISK CATEGORIES OF DRUGS DURING PREGNANCY ». Asian Journal of Pharmaceutical and Clinical Research 10, no 7 (1 juillet 2017) : 77. http://dx.doi.org/10.22159/ajpcr.2017.v10i7.16539.
Texte intégralButler, O. D., Woodrow M. Knight et Jack C. Taylor. « The Regulation of Production Drugs by the Food and Drug Administration ». Professional Animal Scientist 2, no 1 (juin 1986) : 14–17. http://dx.doi.org/10.15232/s1080-7446(15)32415-3.
Texte intégralBlankfield, Robert P., et Imran H. Iftikhar. « Food and Drug Administration Regulation of Drugs That Raise Blood Pressure ». Journal of Cardiovascular Pharmacology and Therapeutics 20, no 1 (6 mai 2014) : 5–8. http://dx.doi.org/10.1177/1074248414531852.
Texte intégralAshley, Donald D. « Clarifying Misconceptions About US Food and Drug Administration Unapproved Drugs Program ». Anesthesia & ; Analgesia 127, no 6 (décembre 2018) : 1292–94. http://dx.doi.org/10.1213/ane.0000000000003852.
Texte intégralThèses sur le sujet "FOOD AND DRUGS ADMINISTRATION"
Li, Hoi-kwong. « Filing of complaints by the US Food and Drug Administration / ». View the Table of Contents & ; Abstract, 2005. http://sunzi.lib.hku.hk/hkuto/record/B35082471.
Texte intégralLi, Hoi-kwong, et 李海光. « Filing of complaints by the US Food and Drug Administration ». Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2005. http://hub.hku.hk/bib/B45010766.
Texte intégralLamb, James Alexander. « Under-reporting of Adverse Drug Reactions to the Food & ; Drug Administration ». ScholarWorks, 2018. https://scholarworks.waldenu.edu/dissertations/6055.
Texte intégralWang, Bo. « Clinical Evidence Supporting Pharmacogenomic Biomarker Testing Provided in US Food and Drug Administration Drug Labels ». Thesis, Harvard University, 2016. http://nrs.harvard.edu/urn-3:HUL.InstRepos:27007749.
Texte intégralRichert, Lucas. « Pills, politics, and pitfalls : The food and drug administration during the Reagan years ». Thesis, University of London, 2010. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.536790.
Texte intégralMayhew, Brian Michael. « An evaluation of the food and drug administration’s expedited pathways ». reponame:Repositório Institucional do FGV, 2016. http://hdl.handle.net/10438/17995.
Texte intégralApproved for entry into archive by Janete de Oliveira Feitosa (janete.feitosa@fgv.br) on 2017-02-22T12:15:27Z (GMT) No. of bitstreams: 1 Brian Mayhew.pdf: 2184085 bytes, checksum: fde6f5caf45ebd8577ed334ed2f2ebb3 (MD5)
Made available in DSpace on 2017-03-03T12:58:39Z (GMT). No. of bitstreams: 1 Brian Mayhew.pdf: 2184085 bytes, checksum: fde6f5caf45ebd8577ed334ed2f2ebb3 (MD5) Previous issue date: 2016-11-09
Biopharmaceutical development is characterized by challenging regulations, intense competition and significant costs that result in the need for biopharmaceutical companies to consistently produce innovation biopharmaceutical products. The United States Congress has sought to provide a balanced environment that combines significant regulatory oversight by the US Food and Drug Administration (FDA) with market-based incentives (patent protection, exclusivity) and expedited pathways (accelerated approval, breakthrough designation, fast track designation, and priority review) that seek to quickly identify and move innovative new medicines through development that will address unmet medical need and treat serious or life-threatening diseases or conditions. While FDA’s expedited programs are believed to accelerate the development of innovative drug products, the programs have not been formally measured against their intended purpose: more efficient development and regulatory reviews. This thesis research project attempts to effectively measure FDA’s expedited programs by cataloguing FDA approvals from 1987-2015, measuring development and regulatory review time, and drawing conclusions and making recommendations based on the statistical analyses generated from the project.
Garmendia, Craig A. « Patterns of Regularity Noncompliance Identified by the U.S. Food and Drug Administration and Their Effects on Meta-analyses ». FIU Digital Commons, 2018. https://digitalcommons.fiu.edu/etd/3920.
Texte intégralBalmaceda, Zaira, et Kathy Lin. « Comparison of Findings from Published Weight Loss Trials for Orlistat to the Findings Used by the Food and Drug Administration (FDA) ». The University of Arizona, 2010. http://hdl.handle.net/10150/623796.
Texte intégralOBJECTIVES: The objective was to compare differences in weight loss data presented in published orlistat studies on orlistat to their corresponding studies submitted to the FDA. METHODS: This meta-‐analysis compared one-‐year weight loss data reported in six published orlistat 120 mg studies to data reviewed by the FDA in the New Drug Application (NDA). The primary dependent variables were the percentage of subjects achieving 5% and 10% weight loss. Prior to analysis, weight loss data was stratified into placebo and orlistat groups. Potential for bias was assessed with a funnel plot and by calculating Kendall’s tau. The a priori alpha level was 0.05. RESULTS: Corresponding FDA reviews were located for 6 published orlistat trials. The pooled odds ratio of published vs. FDA 5%weight loss data for the placebo arm was 2.18 (95% CI: 1.83 to 2.60; p < 0.001) and 1.95 (95% CI: 1.70 to 2.24; p < 0.001) for the orlistat arm. The pooled odds ratio of published vs. FDA for 10% weight loss data for the placebo arm was 2.25 (95% CI: 1.74 to 2.91; p < 0.001) and 2.20 (95% CI: 1.88 to 2.57; p < 0.001) for the orlistat arm. The p-‐values for Kendall’s tau for the 5% and 10% weight loss data were 0.054 and 0.34, respectively. CONCLUSIONS: Published orlistat trials presented 5% and 10% weight loss data that were twice of that reported in the FDA-‐reviewed trials, and there was potential for bias in the 5% weight loss data.
Noh, In Joon. « Essays on Drivers of Quality and Compliance Performance in the Pharmaceutical Industry : Policy, Manufacturing Strategy, and Organizational Learning Perspectives ». The Ohio State University, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=osu1595014194719331.
Texte intégralBarrett, Jane A. « Applying strategles of architectural androgeny to a renovation of and addition to an existing building currently occupied by the food and drug administration ». Thesis, Georgia Institute of Technology, 1994. http://hdl.handle.net/1853/23446.
Texte intégralLivres sur le sujet "FOOD AND DRUGS ADMINISTRATION"
O'Reilly, James T. Food and drug administration. 2e éd. [Eagan, MN] : Thomson/West, 2005.
Trouver le texte intégralO'Reilly, James T. Food and drug administration. 2e éd. [St. Paul, Minn.] : Thomson/West, 2005.
Trouver le texte intégralO'Reilly, James T. Food and drug administration. 2e éd. Colorado Springs, Colo : Shepard's/McGraw-Hill, 1993.
Trouver le texte intégralThe Food and Drug Administration. New York, N.Y : Chelsea House, 1988.
Trouver le texte intégralA, Rettig Richard, Earley Laurence E, Merrill Richard A et Institute of Medicine (U.S.). Division of Health Sciences Policy., dir. Food and Drug Administration advisory committees. Washington, D.C : National Academy Press, 1992.
Trouver le texte intégralCenter for Drug Evaluation and Research (U.S.), dir. Drugs@FDA. Washington D.C : U.S. Food and Drug Administration, Center for Drug and Evaluation Research, 2004.
Trouver le texte intégralBuchta, Teresa M. Food and Drug Administration, Cincinnati, Ohio. [Atlanta, Ga.?] : U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, 1992.
Trouver le texte intégralUnited States. Food and Drug Administration. Cincinnati District Office et National Institute for Occupational Safety and Health, dir. Food and Drug Administration, Cincinnati, Ohio. [Atlanta, Ga.?] : U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, 1992.
Trouver le texte intégralBuchta, Teresa M. Food and Drug Administration, Cincinnati, Ohio. [Atlanta, Ga.?] : U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, 1992.
Trouver le texte intégralPhilipson, Tomas J. Is the Food and Drug Administration safe and effective ? Cambridge, Mass : National Bureau of Economic Research, 2007.
Trouver le texte intégralChapitres de livres sur le sujet "FOOD AND DRUGS ADMINISTRATION"
Gibbs, Jeffrey N., Iver P. Cooper et Bruce F. Mackler. « Food and Drug Administration ». Dans Biotechnology & ; the Environment : International Regulation, 115–24. London : Macmillan Education UK, 1987. http://dx.doi.org/10.1007/978-1-349-09160-7_7.
Texte intégralGressner, A. M., et O. A. Gressner. « Food and Drug Administration ». Dans Lexikon der Medizinischen Laboratoriumsdiagnostik, 1. Berlin, Heidelberg : Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-49054-9_1160-1.
Texte intégralGressner, A. M., et O. A. Gressner. « Food and Drug Administration ». Dans Springer Reference Medizin, 899. Berlin, Heidelberg : Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_1160.
Texte intégralNahler, Gerhard. « Food and Drug Administration (FDA) ». Dans Dictionary of Pharmaceutical Medicine, 76. Vienna : Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_574.
Texte intégralGooch, Jan W. « Food and Drug Administration (FDA) ». Dans Encyclopedic Dictionary of Polymers, 321. New York, NY : Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6247-8_5212.
Texte intégralDesanto, Barbara. « US Food and Drug Administration ». Dans The Palgrave Encyclopedia of Interest Groups, Lobbying and Public Affairs, 1450–55. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-44556-0_227.
Texte intégralPati, Sandipan, et Steve S. Chung. « Approach of the Food and Drug Administration in Development of Antiepileptic Drugs ». Dans Atlas of Epilepsies, 1609–13. London : Springer London, 2010. http://dx.doi.org/10.1007/978-1-84882-128-6_242.
Texte intégralWeissinger, Judi. « Assessment of Reproductive Toxicology of Drugs at the Food and Drug Administration ». Dans Risk Assessment of Prenatally-Induced Adverse Health Effects, 103–11. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77753-0_7.
Texte intégralBlock, Walter E. « The Food and Drug Administration Challenger ». Dans Defending the Undefendable III, 137–39. Singapore : Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-3957-9_38.
Texte intégralLi, Haodi, Qingcai Chen, Buzhou Tang, Dong Huang, Xiaolong Wang et Zengjian Liu. « An Initial Ingredient Analysis of Drugs Approved by China Food and Drug Administration ». Dans Communications in Computer and Information Science, 104–9. Singapore : Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-3168-7_10.
Texte intégralActes de conférences sur le sujet "FOOD AND DRUGS ADMINISTRATION"
Tapia, J. Carlos, Consolación Molto, Aida Bujosa, Arnoud J. Templeton, Agustí Barnadas, Eithan Amir et Ariadna Tibau. « Abstract PD10-06 : Clinical benefit of breast cancer drugs approved by the United States Food and Drug Administration ». Dans Abstracts : 2019 San Antonio Breast Cancer Symposium ; December 10-14, 2019 ; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-pd10-06.
Texte intégralRose, Charles L. « The food and drug administration (FDA) submission process ». Dans ICALEO® ‘86 : Proceedings of the Medicine and Surgery Symposium. Laser Institute of America, 1986. http://dx.doi.org/10.2351/1.5057788.
Texte intégralAlbuquerque, Pedro José Honório de, Laura Guerra Lopes, Jordy Silva de Carvalho, Luzilene Pereira de Lima et Marina Galdino da Rocha Pitta. « Emerging therapies for amyotrophic lateral sclerosis applied to drug discovery ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.021.
Texte intégralPera, V., P. Rijnbeek, J. Van Der Lei, J. Kors, R. Parry, E. Van Mulligen, M. De Wilde, G. Brusselle, G. Brusselle et K. Verhamme. « Characteristics of medication errors among respiratory drugs within the Food and Drug Administration’s Adverse Event Reporting System ». Dans ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.283.
Texte intégralEtan, Tal, Eitan Amir, Adriana Tibau, Rinat Yerushalmi, Assaf Moore, Daniel Shepshelovich et Hadar Goldvaser. « Abstract PS14-13 : National comprehensive cancer network (NCCN) recommendations for drugs without US food and drug administration (FDA) approval in metastatic breast cancer : A cross-sectional study ». Dans Abstracts : 2020 San Antonio Breast Cancer Virtual Symposium ; December 8-11, 2020 ; San Antonio, Texas. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.sabcs20-ps14-13.
Texte intégralBeekman, Jessica, Samantha Popol, Shaun MacMahon et Steven Peyton. « Analysis of MCPD and Glycidyl Esters : Recent Occurrence Data in U.S. Infant Formulas and Effects of Cooking on Contaminant Concentrations in Frozen Fried Foods ». Dans 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/jsat7828.
Texte intégralHudson, B. J. « Exporting medical devices to the USA (how to do business with the Food and Drug Administration) ». Dans IEE Seminar Exporting Medical Devices to the USA : A Practical Guide to the FDA Regulations. IEE, 1998. http://dx.doi.org/10.1049/ic:19980988.
Texte intégralLueddemann, Tobias, Diqing Chang, Sadik Sahin et Tim C. Lueth. « Medical device approval process in China since the introduction of the China Food and Drug Administration ». Dans 2016 IEEE Symposium on Product Compliance Engineering (ISPCE). IEEE, 2016. http://dx.doi.org/10.1109/ispce.2016.7492842.
Texte intégralSanders, Michael J. « Aseptic Processing and Handling of Citrus Juice ». Dans ASME 1990 Citrus Engineering Conference. American Society of Mechanical Engineers, 1990. http://dx.doi.org/10.1115/cec1990-3606.
Texte intégralEakin, Cortney, Cheng-I. Liao, Joshua Cohen, Ritu Salani, Daniel Kapp et John K. Chan. « O013/#813 Trends of metastatic leiomyosarcoma following the us food and drug administration (FDA) warning on laparoscopic power morcellators ». Dans IGCS 2022 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-igcs.15.
Texte intégralRapports d'organisations sur le sujet "FOOD AND DRUGS ADMINISTRATION"
Philipson, Tomas, et Eric Sun. Is the Food and Drug Administration Safe and Effective ? Cambridge, MA : National Bureau of Economic Research, octobre 2007. http://dx.doi.org/10.3386/w13561.
Texte intégralBlanchard, A. Derived Intervention Levels for Tritium Based on Food and Drug Administration Methodology. Office of Scientific and Technical Information (OSTI), décembre 1998. http://dx.doi.org/10.2172/4840.
Texte intégralDEPARTMENT OF DEFENSE WASHINGTON DC. Application of Food and Drug Administration (FDA) Rules to Department of Defense Force Health Protection Programs. Fort Belvoir, VA : Defense Technical Information Center, février 2008. http://dx.doi.org/10.21236/ada594572.
Texte intégralBlanchard, A. Derived Intervention Levels for Tritium Based on Food and Drug Administration Methodology Using ICRP 56 Dose Coefficients. Office of Scientific and Technical Information (OSTI), juin 1999. http://dx.doi.org/10.2172/7962.
Texte intégralMiller, Patrice, et Alexis Williams. COVID-19’s Impact on Clinical Research. RTI Press, décembre 2022. http://dx.doi.org/10.3768/rtipress.2022.rb.0032.2212.
Texte intégralHuang, Jinsheng, Teng Fan, Yuming Rong, Xujia Li, Qi Jiang, Jun Kan, Huijuan Qiu, Qi Quan, Bei Guo et Guifang Guo. Efficacy of Aidi injection combined with chemotherapy, radiotherapyor chemoradiotherapy for unresectable esophageal cancer treatment : A meta-analysis and systematic review of 29 randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septembre 2022. http://dx.doi.org/10.37766/inplasy2022.9.0020.
Texte intégralGupta, Aditya, Tong Wang, Shruthi Ravi, Mesbah Talukder, Jessie Carviel et Mary Bamimore. Relative efficacy of microneedling in the treatment of pattern hair loss : a protocol for a systematic review with network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septembre 2022. http://dx.doi.org/10.37766/inplasy2022.9.0042.
Texte intégralLaw, Marc, et Gary Libecap. The Determinants of Progressive Era Reform : The Pure Food and Drugs Act of 1906. Cambridge, MA : National Bureau of Economic Research, décembre 2004. http://dx.doi.org/10.3386/w10984.
Texte intégralDeng, Jianhao, jiaxing Zhang, QingXia Zhang et Guowei Zhong. Serotonin syndrome with dextromethorphan alone and in combination with other serotonergic drugs. a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, mai 2022. http://dx.doi.org/10.37766/inplasy2022.5.0079.
Texte intégralBergwerff, A. Residues of veterinary drugs in food : keynote, oral and poster contributions : proceedings of the EuroResidue VIII conference Egmond aan Zee, The Netherlands 23-25 May, 2016. Wageningen : Wageningen UR, 2016. http://dx.doi.org/10.18174/370325.
Texte intégral